Back to Search
Start Over
SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma.
- Source :
- Immunotherapy (1750743X); Mar2024, Vol. 16 Issue 4, p243-256, 14p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 1750743X
- Volume :
- 16
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Immunotherapy (1750743X)
- Publication Type :
- Academic Journal
- Accession number :
- 175192371
- Full Text :
- https://doi.org/10.2217/imt-2023-0130